Connect with us

Technology

QL Biopharm Announces Abstract on Novel Ultra Long-acting GLP-1RA to be Presented at EASD Annual Meeting 2024

Published

on

– Abstract on data from a two-part phase 1c, multiple ascending dose study accepted for oral presentation –

– New data highlighting the Company’s lead drug candidate ZT002 for obesity –

BEIJING, Sept. 3, 2024 /PRNewswire/ — Beijing QL Biopharmaceutical Co., Ltd. (“QL Biopharm”), a clinical stage biopharmaceutical company developing innovative biologic drugs for the treatment of metabolic diseases, today announces that an abstract on its lead drug candidate ZT002 will be presented at the European Association for the Study of Diabetes (EASD) Annual Meeting 2024, Madrid, Spain on Thursday 12 September 2024.

QL Biopharm’s lead asset, ZT002 is a novel ultra long-acting glucagon-like peptide-1 receptor agonist (“GLP-1 RA”) in development for obesity with monthly subcutaneous administration. The phase 1c, randomized, placebo-controlled, double-blind multiple ascending dose study was conducted in 28 patients with obesity. Patients were randomly assigned to receive either ZT002 or placebo. Results from the study showed that ZT002 had a favorable safety and tolerability profile. Further, ZT002 induced clinically meaningful weight loss with associated cardiometabolic improvements.

Dr. Zhang Xujia, Ph.D., Founder, Chairman and Chief Executive Officer of QL Biopharm said: “The emerging profile of ZT002 holds great promise as a new standard of care for patients living with obesity. The safety and tolerability seen in patients receiving ZT002 is aligned with the GLP-1RA class. ZT002 has the potential to simplify obesity treatment. We look forward to advancing our ongoing studies and further exploring the potential of ZT002 for weight management and type 2 diabetes treatment.”

Details of the EASD Annual Meeting 2024 poster presentation are as follows:

Title: ZT002, a novel ultra long-acting glp-1 receptor agonist in adults with overweight or obesity: a randomized, placebo-controlled, multiple ascending dose phase 1c study

Session: OP 25 Incretin receptor agonists: better and better

Date and Time: Thursday, 12 September 2024, 11:15 – 11:30 CEST

Presenter: Linong Ji, MD, Professor of Medicine at Peking University People’s Hospital

Location: Madrid Hall

Abstract Number: 147

For more information about the EASD Annual Meeting 2024, including details related to accepted abstracts and presentations, please visit its website. The Abstract is available on the EASD online planner here.

NOTES TO EDITORS

About QL Biopharm

QL Biopharm is a clinical-stage biopharmaceutical company focused on developing novel best-in-class peptide therapeutics for metabolic diseases. The Company leverages its proprietary E. coli manufacturing process enabling rapid and cost-effective scaling of manufacturing for high volume markets. The lead drug candidate, ZT002, is an ultra long-acting subcutaneously administered GLP-1 receptor agonist, currently in a Phase 2 study for obesity and in Phase 1 for type 2 diabetes. In Phase 1 studies, ZT002 demonstrated compelling weight loss and tolerability consistent with the GLP-1 RA class. The Company is also advancing a broader portfolio of novel preclinical assets for the treatment of metabolic diseases, in addition to its biosimilar semaglutide program, currently in Phase 3. QL Biopharm is led by a team of pharma industry veterans with expertise in E. coli–based peptide manufacturing and the development of drugs for metabolic diseases. The Company is backed by leading professional life science investors.

For additional information, please visit https://qlbiopharm.com/

About EASD

The European Association for the Study of Diabetes e.V. (EASD) is a membership-based academic non-profit organization. It was founded in 1965 and its headquarters is based in Duesseldorf, Germany. The aims of the Association are to encourage and support research in the field of diabetes, the rapid diffusion of acquired knowledge and to facilitate its application.

View original content:https://www.prnewswire.co.uk/news-releases/ql-biopharm-announces-abstract-on-novel-ultra-long-acting-glp-1ra-to-be-presented-at-easd-annual-meeting-2024-302236190.html

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

In Turfan, Xinjiang, China’s first commercially operated microgrid has generated nearly 100 million kWh of electricity

Published

on

By

TURFAN, China, Nov. 15, 2024 /PRNewswire/ — On November 13, the Turfan New Energy City Microgrid Demonstration Project, China’s first commercially operated microgrid demonstration project, generated nearly 100 million kWh of electricity, equivalent to saving 29,000 tons of standard coal and reducing carbon dioxide emissions by 77,600 tons.

A microgrid refers to a small-scale power generation and distribution system organized by distributed power sources, power loads, distribution facilities, monitoring and protection devices, etc., which can realize flexible control and autonomous management. Since the end of 2013, the project had been the largest and most comprehensive solar energy utilization and building integration project in China up to that time, with 8.7 MW of photovoltaic power installed on the roofs of 223 residential buildings, generating an annual power capacity of about 10 million kWh.

To promote the physical operation of the project, the State Grid Turfan Power Supply Company invested more than 2 million yuan to cooperate in the construction of microgrid infrastructure, fully supporting the online operation of surplus new energy power generation, promoting the comprehensive utilization of renewable resources in urban buildings, and helping Turfan build a high-quality development demonstration area and a green and low-carbon pilot area.

View original content:https://www.prnewswire.com/apac/news-releases/in-turfan-xinjiang-chinas-first-commercially-operated-microgrid-has-generated-nearly-100-million-kwh-of-electricity-302306810.html

SOURCE State Grid Turfan Power Supply Company

Continue Reading

Technology

Innovations in Guiyang: Adhering to New Industrialization and Promoting High-End, Intelligent and Green Manufacturing

Published

on

By

GUIYANG, China, Nov. 15, 2024 /PRNewswire/ — A report by Huanqiu.com

The wave of new industrialization in Guiyang is driving the transformation and upgrading of the manufacturing industry in ways like never before. Guiyang is always strategically oriented toward “industrial structure optimization with a focus on industries”, and has made all efforts to develop “four major industrial bases”, highlighting its industrial economy as the “primary driving force” behind development. Especially relying on its policy edge in renewable energy, Guiyang has rapidly emerged as a national new-energy power battery and materials research, development and production center, injecting strong momentum into the city’s economy.

In October 2023, the CATL (Guizhou) New Energy Power and Energy Storage Battery Production Base, located in Gui’an New Area, Guizhou Province, was put into production. The first phase of the base boasts cutting-edge design standards, characterized by “lighthouse + zero carbon factory”. The high-standard facility employs advanced, high-speed, highly automated, and flexible production lines. It is designed to have an annual production capacity of 30 GWh. After the base achieves the designed production capacity, its annual output value is expected to reach 15 billion yuan. According to statistics, the base realized an industrial output value of 618 million yuan in the first half of 2024, and the year’s industrial output value is expected at about 2 billion yuan.

The Chery (Guizhou) industrial base has also yielded unusually brilliant results in the field of new energy vehicles (NEVs), where Chery Automobile’s self-developed “CHEVOO” new-generation light truck KL71 project is undergoing four-pillar car road tests. The advanced pressing, welding, painting and assembly lines, as well as the R&D lab and the all-electric truck production line, together constitute this “digital intelligent” NEV factory. Moreover, the Chery (Guizhou) industrial base has built, extended and strengthened its vehicle manufacturing industry chain so as to master key parts supply chains and reduce development costs.

The Gui’an FinDreams battery project, as an important move of BYD in Guiyang, is also showing its strength in power batteries for NEVs. FinDreams Battery Co., Ltd. at Longshan Industrial Park in Gui’an New Area has four automatic production lines that are operating at high speeds in the workshop, which produce “blade batteries” which are well-known both in and out of the industry. According to reports, 300 battery packs and 40,000 cells can be produced per day.

Guiyang’s “four bases” – a new energy vehicles and battery materials production base, a resource deep-processing base, a computing power assurance base, and an industrial backup base, contribute greatly to the development of NEV and battery materials industry, electronic information manufacturing industry, and advanced equipment manufacturing industry, etc. Data show that in the first three quarters, the added value of Guiyang’s industrial enterprises above designated size grew by 11%, and the contribution of industrial economy to economic growth reached 39.4%.

Photo – https://mma.prnewswire.com/media/2558773/image.jpg 

View original content:https://www.prnewswire.co.uk/news-releases/innovations-in-guiyang-adhering-to-new-industrialization-and-promoting-high-end-intelligent-and-green-manufacturing-302306825.html

Continue Reading

Technology

Premialab appointed by Lombard Odier Investment Managers to scale Quantitative Investment Strategies

Published

on

By

Premialab’s technology chosen to enhance QIS scaling, operational efficiency, and risk management.

PARIS, Nov. 15, 2024 /PRNewswire/ — Lombard Odier Investment Managers (LOIM), the institutional asset management business of the Lombard Odier Group, has integrated Premialab‘s industry-leading technology to support the management of their soon-to-be-launched DOM Global Macro strategy. This partnership underscores LOIM’s commitment to onboard innovative strategies in an evolving market landscape.

“Our decision to partner with Premialab is driven by their comprehensive risk management and regulatory compliance expertise,” said Didier Anthamatten, Portfolio Manager at LOIM. “With a strong track record in alternative investments, LOIM remains focused on delivering innovative investment solutions and high-quality returns for our clients. Premialab’s advanced data capabilities are essential in helping us maintain our rigorous standards and provide robust, risk-adjusted performance. Additionally, their platform perfectly matches the DOM Global Macro strategy’s needs, enhancing our risk monitoring capabilities and streamlining portfolio management.”

The DOM Global Macro strategy expects to leverage Premialab’s unique dataset. The full lookthrough across all DOM’s proprietary systematic strategies allows granular risk decomposition and scenario-based analysis at the entire portfolio level. This should help monitoring exposures’ attractiveness, from both time-series and cross-sectional perspectives, and optimizing asset allocation.

Neil Richards, Head of EMEA Business Development at Premialab, said the collaboration with LOIM is a significant addition to Premialab’s growing business in Switzerland and within the wider European markets.

“Institutions such as LOIM, which oversees a substantial portfolio across various asset classes, need continuous monitoring and adjustment to keep their investments on track,” he explained. “Premialab provides the tools for benchmarking and stress testing their systematic investments, ensuring that LOIM’s mandates are effectively managed in terms of cost, risk, and value.”

Premialab CEO Adrien Géliot highlighted that the QIS sector is experiencing rapid growth, driven by institutional investors seeking liquid, transparent, and cost-efficient investment strategies. “Premialab sits at the centre of the QIS landscape, uniquely positioned to aggregate and make sense of the vast and growing universe of data,” he stated. “We are thrilled to be partnering with LOIM to deliver our unique data and risk monitoring capabilities to one of the top global investment firms.”

Premialab’s multi-asset, multi-region platform handles 10 million data points daily. It analyzes over 5,000 investible systematic strategies, with client assets under management totalling approximately USD $20 trillion. Combining the Premialab platform with Premialab Pure Factors®, it provides comprehensive cross-asset quantitative strategy selection and thorough due diligence on strategies available worldwide. Additionally, the platform enhances risk management and reporting capabilities, including expedited and detailed regulatory reporting.

With its unique combination of systematic strategies and discretionary trading, the DOM Global Macro strategy clearly benefits from Premialab’s state-of-the art data analysis capabilities and computational efficiency. The Portfolio and Risk Managers can thus use a shared dataset for risk analysis and performance decomposition, enhancing the portfolio’s robustness and operational efficiency.

About Premialab
Premialab is the leading independent platform that collaborates with leading investment banks and institutional investors globally, providing data, analytics, and risk solutions for systematic, factor, and multi-asset strategies. With offices in London, Paris, New York, Hong Kong, Dubai and Sydney, the company has forged strong partnerships with the top 18 investment banks, asset managers, pension funds, sovereign wealth funds and insurance companies globally.

About Lombard Odier Investment Managers (LOIM)
Lombard Odier Investment Managers (LOIM) is the institutional asset management business of the Lombard Odier Group, wholly owned and funded by its partners since its establishment in 1796.

We provide a range of investment solutions to a diverse group of long-term oriented clients. Our heritage, and our combination of the best of conservatism and innovation, keeps us well positioned to create lasting value for our clients. Our investment capabilities span fixed income, convertible bonds, equities, multi-asset, and alternatives. Sustainability is central to our investment philosophy; we believe it is the founding principle of long-term economic and investment outcomes and will drive returns over the long term.

With over 200 investment professionals, we are a global business with a network of 13 offices across Europe, Asia and North America and have assets under management of CHF 64 billion (as at 31 September 2024).

View original content:https://www.prnewswire.com/de/pressemitteilungen/premialab-appointed-by-lombard-odier-investment-managers-to-scale-quantitative-investment-strategies-302306411.html

Continue Reading

Trending